Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

MLA

Unit Opleiding Aios, et al. Nivolumab plus Brentuximab Vedotin +/- Bendamustine Combination Therapy: A Safe and Effective Treatment in Pediatric Recurrent and Refractory Classical Hodgkin Lymphoma. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432122521&authtype=sso&custid=ns315887.

APA

Unit Opleiding Aios, Infection & Immunity, CTI Boes, PMC Medisch specialisten, Zorg en O&O, Child Health, CTI Peperzak, Cancer, Greve, P., Beishuizen, A., Hagleitner, M., Loeffen, J., Veening, M., Boes, M., Peperzak, V., Diez, C., & Meyer-Wentrup, F. (2023). Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.

Chicago

Unit Opleiding Aios, Infection & Immunity, CTI Boes, PMC Medisch specialisten, Zorg en O&O, Child Health, CTI Peperzak, et al. 2023. “Nivolumab plus Brentuximab Vedotin +/- Bendamustine Combination Therapy: A Safe and Effective Treatment in Pediatric Recurrent and Refractory Classical Hodgkin Lymphoma.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432122521&authtype=sso&custid=ns315887.